Heunisch Fabian, von Einem Gina, Alter Markus, Weist Andreas, Dschietzig Thomas, Kretschmer Axel, Hocher Berthold
Center for Cardiovascular Research, Charité, Berlin, Germany.
Center for Cardiovascular Research, Charité, Berlin, Germany; Department of Nephrology, Campus Benjamin Franklin, Charité, Berlin, Germany.
Life Sci. 2014 Nov 24;118(2):440-5. doi: 10.1016/j.lfs.2013.12.233. Epub 2014 Jan 12.
Contrast media-induced nephropathy (CIN) is associated with increased morbidity and mortality. The renal endothelin system has been associated with disease progression of various acute and chronic renal diseases. However, robust data coming from adequately powered prospective clinical studies analyzing the short and long-term impacts of the renal ET system in patients with CIN are missing so far. We thus performed a prospective study addressing this topic.
We included 327 patients with diabetes or renal impairment undergoing coronary angiography. Blood and spot urine were collected before and 24 h after contrast media (CM) application. Patients were followed for 90 days for major clinical events like need for dialysis, unplanned rehospitalization or death.
The concentration of ET-1 and the urinary ET-1/creatinine ratio decreased in spot urine after CM application (ET-1 concentration: 0.91±1.23 pg/ml versus 0.63±1.03 pg/ml, p<0.001; ET-1/creatinine ratio: 0.14±0.23 versus 0.09±0.19, p<0.001). The urinary ET-1 concentrations in patients with CIN decreased significantly more than in patients without CIN (-0.26±1.42 pg/ml vs. -0.79±1.69 pg/ml, p=0.041), whereas the decrease of the urinary ET-1/creatinine ratio was not significantly different (non-CIN patients: -0.05±0.30; CIN patients: -0.11±0.21, p=0.223). Urinary ET-1 concentrations as well as the urinary ET-1/creatinine ratio were not associated with clinical events (need for dialysis, rehospitalization or death) during the 90 day follow-up after contrast media exposure. However, the urinary ET-1 concentration and the urinary ET-1/creatinine ratio after CM application were higher in those patients who had a decrease of GFR of at least 25% after 90 days of follow-up.
In general the ET-1 system in the kidney seems to be down-regulated after contrast media application in patients with moderate CIN risk. Major long-term complications of CIN (need for dialysis, rehospitalization or death) are not associated with the renal ET system.
造影剂肾病(CIN)与发病率和死亡率增加相关。肾内皮素系统与各种急慢性肾脏疾病的疾病进展有关。然而,迄今为止,尚无来自足够样本量的前瞻性临床研究的有力数据来分析肾内皮素系统对CIN患者的短期和长期影响。因此,我们进行了一项针对该主题的前瞻性研究。
我们纳入了327例接受冠状动脉造影的糖尿病或肾功能损害患者。在应用造影剂(CM)前及应用后24小时采集血液和随机尿样。对患者进行90天的随访,观察主要临床事件,如是否需要透析、非计划再次住院或死亡。
应用CM后随机尿中ET-1浓度及尿ET-1/肌酐比值降低(ET-1浓度:0.91±1.23 pg/ml对0.63±1.03 pg/ml,p<0.001;ET-1/肌酐比值:0.14±0.23对0.09±0.19,p<0.001)。CIN患者尿ET-1浓度的降低幅度明显大于非CIN患者(-0.26±1.42 pg/ml对-0.79±1.69 pg/ml,p=0.041),而尿ET-1/肌酐比值的降低无显著差异(非CIN患者:-0.05±0.30;CIN患者:-0.11±0.21,p=0.223)。在造影剂暴露后的90天随访期间,尿ET-1浓度及尿ET-1/肌酐比值与临床事件(需要透析、再次住院或死亡)无关。然而,在随访90天后肾小球滤过率至少降低25%的患者中,应用CM后的尿ET-1浓度及尿ET-1/肌酐比值较高。
一般来说,在中度CIN风险患者中应用造影剂后,肾脏中的ET-1系统似乎下调。CIN的主要长期并发症(需要透析、再次住院或死亡)与肾内皮素系统无关。